The UK and US have signed a key bilateral deal that will guarantee zero tariffs on British drug products being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This commitment guarantees that tariffs on these vital exports will remain at nothing for a period of three years.
This agreement is in response to recent threats to significantly raise import taxes on patented drug imports, with increases floated up to 100%.
"This deal with the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue fairness to U.S.–U.K. drug exports," a statement declared.
Commercial Importance
Medicines represent one of the Britain's largest exports to the US, which is easily the biggest destination for major companies like GSK and AstraZeneca.
Export figures show that in the 12 months to the end of the third quarter, the UK exported medicines totaling over eleven billion pounds to the US. This amount represented nearly one-fifth of British export trade in that period.
"This guarantee safeguards work, boosts capital expenditure and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Detailed UK Commitments
The pact entails several notable commitments from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to double total public funding on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at 15%. Last year, refunds topped twenty percent.
Industry Background
This agreement comes amid a ongoing tension between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
These tensions were intensified by claims that US customers were paying several times more for the same drugs than patients in the other developed nations.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while substantial expansions have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
